BRAF and non-small cell lung carcinoma: Our study can support these findings, which affects the evolution and treatment of the disease, considering that many cases with this subtype of NSCLC demonstrate positive results for targetable driver mutations such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, and ROS1.